share_log

Vertex Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Vertex Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

福泰制药 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/05 15:17

Moomoo AI 已提取核心信息

Vertex Pharmaceuticals reported robust Q3 2024 financial results, with total product revenues increasing 12% to $2.77 billion compared to $2.48 billion in Q3 2023. The growth was primarily driven by TRIKAFTA/KAFTRIO sales of $2.59 billion, up 14% year-over-year, reflecting strong global demand and higher U.S. pricing. The company also recorded initial CASGEVY revenue of $2.0 million following recent approvals.Research and development expenses rose 8% to $875.9 million as the company advanced multiple clinical programs. Cost of sales increased to 14% of revenue versus 13% last year due to CASGEVY-related expenses. Net income reached $1.05 billion or $4.01 per diluted share, compared to $1.04 billion or $3.97 per share in Q3 2023.The company maintained a strong balance sheet with $11.2 billion in cash and marketable securities as of September 30, 2024. Vertex continues to expand its CF business globally while advancing pipeline programs in sickle cell disease, pain management, and other therapeutic areas. The company has also activated 45 authorized treatment centers globally for CASGEVY and secured multiple reimbursement agreements.
Vertex Pharmaceuticals reported robust Q3 2024 financial results, with total product revenues increasing 12% to $2.77 billion compared to $2.48 billion in Q3 2023. The growth was primarily driven by TRIKAFTA/KAFTRIO sales of $2.59 billion, up 14% year-over-year, reflecting strong global demand and higher U.S. pricing. The company also recorded initial CASGEVY revenue of $2.0 million following recent approvals.Research and development expenses rose 8% to $875.9 million as the company advanced multiple clinical programs. Cost of sales increased to 14% of revenue versus 13% last year due to CASGEVY-related expenses. Net income reached $1.05 billion or $4.01 per diluted share, compared to $1.04 billion or $3.97 per share in Q3 2023.The company maintained a strong balance sheet with $11.2 billion in cash and marketable securities as of September 30, 2024. Vertex continues to expand its CF business globally while advancing pipeline programs in sickle cell disease, pain management, and other therapeutic areas. The company has also activated 45 authorized treatment centers globally for CASGEVY and secured multiple reimbursement agreements.
福泰制药公布了2024年第三季度强劲的财务业绩，产品总营业收入较2023年第三季度的24.8亿增长12%，达到27.7亿。增长主要得益于TRIKAFTA/KAFTRIO的销售额达到了25.9亿，同比上涨14%，反映出强劲的全球需求和更高的美国定价。公司还在最近获得批准后，记录了初步的CASGEVY收入为200万。研究和开发费用上升了8%，达到87590万，因为公司推进了多个临床项目。销售成本从去年的13%升至收入的14%，这与CASGEVY相关费用有关。净利润达到10.5亿，每股稀释后收益为4.01美元，而2023年第三季度为10.4亿，每股收益为3.97美元。截至2024年9月30日，公司保持了112亿现金和可交易证券的稳健资产负债表。福泰制药继续在全球扩展其囊性纤维化业务，同时推进镰状细胞病、疼痛管理和其他治疗领域的管线项目。公司还在全球激活了45个CASGEVY授权治疗中心，并获得了多个报销协议。
福泰制药公布了2024年第三季度强劲的财务业绩，产品总营业收入较2023年第三季度的24.8亿增长12%，达到27.7亿。增长主要得益于TRIKAFTA/KAFTRIO的销售额达到了25.9亿，同比上涨14%，反映出强劲的全球需求和更高的美国定价。公司还在最近获得批准后，记录了初步的CASGEVY收入为200万。研究和开发费用上升了8%，达到87590万，因为公司推进了多个临床项目。销售成本从去年的13%升至收入的14%，这与CASGEVY相关费用有关。净利润达到10.5亿，每股稀释后收益为4.01美元，而2023年第三季度为10.4亿，每股收益为3.97美元。截至2024年9月30日，公司保持了112亿现金和可交易证券的稳健资产负债表。福泰制药继续在全球扩展其囊性纤维化业务，同时推进镰状细胞病、疼痛管理和其他治疗领域的管线项目。公司还在全球激活了45个CASGEVY授权治疗中心，并获得了多个报销协议。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Corcept医疗
    CORT
    -- 99.710
    bluebird bio
    BLUE
    -- 5.220
    Citius Pharmaceuticals
    CTXR
    -- 1.8440
    NLS Pharmaceutics
    NLSP
    -- 1.4504
    Entero Therapeutics
    ENTO
    -- 0.526
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点